Varian launches Halcyon treatment in EU

Varian Medical (NYSE:VAR) said today it launched its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system in the European Union, with the 1st patient being treated in Blegium. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head &neck and other forms of cancer “We are very proud to have partnered with UZ Leuven on making Halcyon treatments available to patients in Europe just two months after the hospital ordered this new system. The treatments beginning at UZ Leuven are another important step in continuing our efforts of advancing cost-effective cancer care worldwide,” Varian oncology systems biz prez Kolleen Kennedy said in a press release. The 1st European procedure with the system was performed at Belgium’s University Hospitals Leuven on an 80-year-old man with head and neck cancer, Varian said. “We selected the Halcyon system because of its potential to accelerate the treatment workflow and allow for a much closer connection between the patient and therapist. Having now completed our first treatments I can say that Halcyon lived up to its promise of a ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Oncology Varian Medical Systems Source Type: news

Related Links:

The purpose of this study was to investigate the dosimetric impact of weight loss in head and neck (H&N) patients and examine the effectiveness of adaptive planning. Data was collected from 22 H&N cancer patients who experienced weight loss during their course of radiotherapy. The robustness of Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) treatment plans were compared including the potential need for replanning. The dosimetric impact of weight loss was evaluated by calculating a verification plan for each patient on an assessment CT scan taken during the course of treatment.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
It is critical that rigorous evaluation of technology in radiation oncology be undertaken during the early stages of implementation or when there is a marked cost differential. Prospective clinical data proving the clinical effectiveness of emerging technology may not be available to guide proper investment and development. In these scenarios, models can be used to simulate expected clinical outcomes and predict comparative effectiveness and cost-effectiveness.1 In this edition of the Red Journal, 2 studies use model-based approaches to compare photon intensity modulated radiation therapy (IMRT) to proton beam therapy (PBT...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
Conclusion: Clinically significant plexopathy was not seen in spite of majority having over 2-years follow-up and a third of patients having dose above the recommended tolerance. Only nodal category independently influenced dose to the brachial plexii.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: Disease evaluation using PET-CT has an overall accuracy of 80%. High baseline SUVmax correlates with worse clinical outcomes. Negative PET-CT at the first follow-up is a predictor for survival.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Trinanjan Basu, Shikha Goyal, Tejinder Kataria, Deepak GuptaJournal of Cancer Research and Therapeutics 2019 15(3):696-699 Over a decade of intensity-modulated radiotherapy (IMRT) improved the toxicity profile among head-and-neck cancer patients and also improved the quality of life (QOL). Several parameters' few subjective and few objectives have documented various aspects related to QOL. Patients surviving beyond a certain period will have few unattended concern. A single questionnaire-based evaluation might answer few untouched issues. This brief communication formulated such an indigenous single-institution scale ...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Head and Neck Cancer Intervention:   Other: Helical intensity-modulated radiotherapy (IMRT) Sponsor:   Institut Claudius Regaud Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: 3D-HDR-BT achieves favorable clinical outcomes with mild late toxicity in patients with locally rNPC. Introduction Nasopharyngeal carcinoma (NPC), a tumor of epithelial origin, is a malignant disease of the head and neck common in southern China, especially in Guangdong province (1). As a result of advances in modern imaging and irradiation techniques, the 5-year overall survival (OS) of patients with newly diagnosed NPC without metastasis has reached 75% after external beam radiotherapy (EBRT) in Asia (2, 3). However, local recurrence, which occurs in 18–40% of patients, remains a major reason for...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Belgium Health | Cancer | Cancer & Oncology | Head and Neck Cancer | Hospitals | Intensity-Modulated Radiation Therapy